Biogen’s Litifilimab Earns FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus—First Targeted Therapy on the Horizon Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous…
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001 Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced that its investigational cell therapy, OpCT-001, has received…
Legend Biotech Showcases Latest Business Developments at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today provided an update on the Company’s recent commercial and clinical progress and outlined its…
BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of…
The agreement aims to improve medicine affordability while supporting U.S.-based manufacturing and pharmaceutical innovation. Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs…
Gordian Bio Enters Research Partnership with Pfizer to Drive Obesity Target Discovery Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to…
Collaboration focuses on advancing cell-specific siRNA therapies for cardiovascular disease treatment. Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small…
Analyses provide deeper insights into outcomes from the ALTAIR study presented at ASCO GI Natera, Inc., a global leader in cell-free DNA and precision medicine, announced that updated analyses from its ALTAIR clinical trial will be presented at the 2026…
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Bolstering Leadership in Rare Diseases, Driving Revenue Growth, and Enhancing Financial Outlook BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for…
Merck Strikes Deal with U.S. Government to Broaden Access to Medicines and Reduce Costs for Americans Merck, known as MSD outside of the United States and Canada, today announced a historic agreement with the Trump administration to ensure its prescription…
Alnylam to Invest $250M in Enzymatic Ligation Platform at U.S. Facility to Meet Global RNAi Demand Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing…
Zoetis Launches Proposed $1.75 Billion Offering of Convertible Senior Notes Zoetis Inc. today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering…